Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
1997
DOI: 10.1074/jbc.272.6.3246
|View full text |Cite
|
Sign up to set email alerts
|

PG-M/Versican-like Proteoglycans Are Components of Large Disulfide-stabilized Complexes in the Axolotl Embryo

Abstract: Large disulfide-stabilized proteoglycan complexes were previously shown to be synthesized by the epidermis of axolotl embryos during stages crucial to subepidermal migration of neural crest cells. We now show that the complexes contain PG-M/versican-like monomers in addition to some other component with low buoyant density. Metabolically 35 S-labeled proteoglycans were extracted from epidermal explants and separated by size exclusion chromatography and density equilibrium gradient centrifugation. The complexes… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
8
0

Year Published

1997
1997
2010
2010

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 13 publications
(8 citation statements)
references
References 54 publications
0
8
0
Order By: Relevance
“…The large chondroitin sulfate proteoglycan versican was initially described in human fibroblasts [Zimmermann and Ruoslahti, 1989] and was then found in a variety of tissues [Yamagata et al, 1993b;Yao et al, 1994;Nara et al, 1997;Stigson et al, 1997;du Cros et al, 1995]. The tissues that contain versican include embryonic tissues such as embryonic lung fibroblasts [Zimmerman and Ruoslahti, 1989]; embryonic aorta, cornea, and skeletal muscle [Yamagata et al, 1993b]; the mesenchymal cell condensation area of limb buds [Kimata et al, 1986;Shinomura et al, 1990]; the perinotochordal Fig.…”
Section: Discussionmentioning
confidence: 98%
“…The large chondroitin sulfate proteoglycan versican was initially described in human fibroblasts [Zimmermann and Ruoslahti, 1989] and was then found in a variety of tissues [Yamagata et al, 1993b;Yao et al, 1994;Nara et al, 1997;Stigson et al, 1997;du Cros et al, 1995]. The tissues that contain versican include embryonic tissues such as embryonic lung fibroblasts [Zimmerman and Ruoslahti, 1989]; embryonic aorta, cornea, and skeletal muscle [Yamagata et al, 1993b]; the mesenchymal cell condensation area of limb buds [Kimata et al, 1986;Shinomura et al, 1990]; the perinotochordal Fig.…”
Section: Discussionmentioning
confidence: 98%
“…PG-M/versican was originally isolated from human fibroblasts and chicken developing limb buds (10 -14) and was later detected in the normal human central nervous system and brain tumors (15)(16)(17). This proteoglycan is made up of a hyaluronan-binding N terminus (G1 domain) and a selectin-like C terminus (G3 domain) with a central sequence for glycosaminoglycan chain modification (14,18,19).…”
mentioning
confidence: 99%
“…8(C) suggests a greater reduction in aggrecan core protein in CL-2B column fractions of the xyloside treated sclera than in the glycosaminoglycan content in the same fractions. One explanation for this apparent discrepancy is that since the DMMB assay measures total sulfated glycosaminoglycans, it is possible that other proteoglycans, such as versican or perlecan, which co-elute from CL-2B with aggrecan (Keller et al, 1987, Stigson, Lofberg andKjellen, 1997) may be less effected by xyloside treatment and might reduce the differences in glycosaminoglycan concentration between the xyloside and control scleral extracts. Additionally, it is possible that the sulfation of aggrecan is altered (i.e.…”
Section: Effect Of Xyloside On Proteoglycan Accumulation In Vivomentioning
confidence: 89%